46P - The role of IL10, IL6 and TNF_ as potential prognostic markers in breast cancer in Tunisia. (46P)

Date 08 December 2017
Event ESMO Immuno-Oncology Congress 2017
Session Lunch & Poster Display session
Topics Cancer Immunology and Immunotherapy
Translational Research
Presenter Jihene Braham
Citation Annals of Oncology (2017) 28 (suppl_11): xi6-xi29. 10.1093/annonc/mdx711
Authors J.A. Braham, M. Balti, B.A. Mouna, A. Manel, A. Zribi, B.N. Sonia, F. Sana, A. Haddaoui
  • Medical Oncology, Military hospital, 1008 - Tunis/TN



Inflammation has a multifaceted role in cancer progression including initiation, promotion and invasion by affecting the immune surveillance and associated signalling pathways. The aim of this study was to measure circulating pro- and anti-inflammatory cytokines (IL 6, TNF-α, and IL10) and their correlation with prognostic factors and progression in breast cancers in Tunisian patients.


Serum samples were prospectively collected from a cohort of sixty breast cancer patients after surgery. Circulating levels of the pro-inflammatory cytokines TNF-α and IL6 were measured with the technique of a solid-phase, two-site chemo-luminescent enzyme immune-metric assay (Immulite 1000, Simens, USA). Serum levels of the anti-inflammatory cytokine IL10 were measured by the ELISA sandwich method.


The mean age of patients was 47 years (20 – 80 years), 17 patients were metastatic (32% in liver). The mean level of cytokines Il6, IL10 and TNF-α were, respectively, 3.31 +/- 4.07 pg/ml (min 1, max 29.30 pg/ml); 6.560+/- 3.50 pg/ml (min 0.880, max 17.925 pg/ml) and 6.90 +/- 2.99 pg/ml (min 3, max 20.30 pg/ml). We found a significant correlation between high level of IL6 and metastatic disease (p = 0.04) especially with liver metastasis (p = 0.003). We found also a significant correlation between high level of TNF-α and lymph node involvement (p = 0.0011). On the other hand there was a significant correlation between high level of IL10 and high SBR grade (p = 0.01).


Our results highlight the role of circulating cytokines of inflammation IL6, TNF-α and IL10 as a potential prognostic biomarkers in breast cancer patients which could contribute to tumor growth and progression. So there was a rationale for the use of cytokine and chemokine blockade, and further investigation of anti-inflammatory drugs in the chemoprevention and treatment of malignant diseases should be carried out.

Clinical trial identification

Legal entity responsible for the study

Military Hospital


Military Hospital of Tunis


All authors have declared no conflicts of interest.